Table 2: Impact of pretransplant risk factors on overall survival.

Risk factorsAMLALLCMLAATotal

Age class
<2011111
20–403.4 (1.0–11.7)1.3 (0.6–2.8)0.9 (0.3–3.0)1.7 (0.7–4.5)1.4 (0.9–2.2)
>403.8 (1.1–13.7)1.4 (0.5–3.9)1.1 (0.3–3.9)1.1 (0.2–5.3)1.4 (0.9–2.2)

Disease stage
Early11111
Intermediate2.1 (0.8–5.4)1.4 (0.6–3.0)1.9 (0.9–4.0)1.5 (1.0–2.2)
Advanced5.1 (2.1–12.8)2.4 (0.9–6.3)2.1 (0.6–6.8)2.0 (1.3–3.1)

Time interval
<12 months11111
>12 months1.8 (0.8–3.8)0.8 (0.4–1.8)1.7 (0.7–4.3)1.4 (0.5–3.5)1.5 (1.1–2.2)

Donor type
HLA11111
Other3.0 (1.3–7.1)1.6 (0.8–3.3)3.6 (1.5–8.6)1.7 (0.6–5.2)2.4 (1.6–3.6)

Gender combination
Other11111
DF/RM2.4 (1.2–5.1)1.9 (0.9–4.0)0.7 (0.3–1.4)0.8 (0.3–2.3)1.1 (0.8–1.7)

ROC curve
AUC0.8020.7430.6310.5900.667

AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; HLA IS: human leukocyte antigen identical sibling; DF/RM: donor female/recipient male; ROC AUC: receiver operating characteristics area under the curve.